ClinicalTrials.gg
TerminatedNCT02968121Updated Jan 12, 2018

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

A Phase 1 interventional study of Brexpiprazole, OPDC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 2 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2018-01-12.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Health services research

Why this study was terminated
Part A of study was completed per protocol. Conduct of Part B of the study (confirmatory phase) was not necessary.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
25th of 28
22 · median 155
Started
2017
with 1 other
Phase 1
8 of 28
1 open now
Registered
23rd of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 25th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 1, and was the 23rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To determine the pharmacokinetics, safety and tolerability of brexpiprazole administered subcutaneously or intramuscularly in adults with schizophrenia.

Read the detailed description

This trial is designed to assess the pharmacokinetics, safety and tolerability of brexpiprazole in the treatment of subjects with schizophrenia. The trial will consist of two parts across 13-36 months. The trial population will include approximately 110 male \& female subjects between 18 and 64 years of age (inclusive) with a diagnosis of schizophrenia as defined by DSM-V criteria.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 64 years of age, inclusive, at the screening visit with a diagnosis of schizophrenia as defined by criteria.
  • between 18 and 35 kg/m\^2 at the screening visit.
  • Good physical health as determined by no deviation from normal.
  • Ability to provide and/or consent obtained from a legally acceptable representative (as required by IRB), prior to the initiation of any protocol-required procedures.
  • Male and female subjects who are surgically sterile, female subjects who have been for at least 12 consecutive months prior to the screening visit, or male subjects/female subjects (of ) who agree to remain abstinent or to practice 2 of the approved methods from the screening visit and for at least 150 days after the dose of IMP for a female subject or 180 days after the dose of IMP for a male subject.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have:
  • Met criteria for substance use disorder within the past 180 days; including alcohol and benzodiazepines, excluding caffeine/nicotine.
  • A positive drug screen for drugs of abuse (excluding stimulants, other prescribed medications, and marijuana [if in investigator's documented opinion the subject does not meet DSM-V criteria for substance use disorder]).
  • Use of more than 1 psychotropic medication at the screening or baseline visit, except for oral brexpiprazole administered during the brexpiprazole tolerability testing (if applicable) and current oral antipsychotic medication.
  • Use of varenicline beyond screening.
  • Subjects who have participated in any clinical trial involving a psychotropic medication within 1 month prior to the administration of IMP or 5 half-lives from last IMP administration whichever is longer.
  • Subjects who have a significant risk of committing suicide based on history, routine psychiatric status examination, investigator's judgment, or who have an answer of "yes" on questions 4 or 5 on the Baseline Version of the C-SSRS.
  • Subjects currently in an acute relapse of schizophrenia as assessed by the investigator.
  • Subjects with a current DSM-V diagnosis other than schizophrenia. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Part A: Single Dose Injection: Subcutaneous

    Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous

    Drug: Brexpiprazole, OPDC-34712

  • Experimental
    Part A: Single Dose Injection: Intramuscular

    Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous

    Drug: Brexpiprazole, OPDC-34712

  • Experimental
    Part B: Cohort 1

    Drug: Brexpiprazole, OPDC-34712 Once, SC or IM

    Drug: Brexpiprazole, OPDC-34712

  • Experimental
    Part B: Cohort 2

    Drug: Brexpiprazole, OPDC-34712 Once, SC or IM

    Drug: Brexpiprazole, OPDC-34712

  • Experimental
    Part B: Cohort 3

    Drug: Brexpiprazole, OPDC-34712 Once, SC or IM

    Drug: Brexpiprazole, OPDC-34712

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Suicidality via Columbia-Suicide Severity Rating Scale

    Baseline version and Since Last Visit version of CSSRS will be completed by trained trial center staff

    Time frame: Part A: Screening to Day 182; Part B: Screening to Day 126

  2. Number of reported Adverse Events (AE)

    Time frame: Part A: 182 days; Part B: 126 days

  3. Clinical Laboratory Tests

    Hematology, serum chemistry, urinalysis, drug screen, etc. will be performed.

    Time frame: Part A: 182 days; Part B: 126 days

  4. Change in physical exam results

    Investigator or designee will perform complete physical exam and document any clinically significant conditions. Body height and weight will also be measured for BMI calculation and weight will be measured as part of all subsequent physical exams.

    Time frame: Part A: Screening to Day 182; Part B: Screening to Day 126

  5. Change in Systolic/Diastolic blood pressure from screening to end of study

    Heart rate and body temperature will also be obtained prior to PK blood draws and ECG.

    Time frame: Part A: Screening to Day 182; Part B: Screening to Day 126

  6. ECG Reading

    12-lead ECG will be collected in triplicate (5 minutes apart). heart rate, ventricular rate, RR interval, PR interval, QRS duration and QT intervals will be recorded. QTcF and corrected QT interval using Bazett's formula will be calculated.

    Time frame: Part A: 182 days; Part B: 126 days

  7. Extrapyramidal Symptoms (EPS) Rating Scale

    SAS, AIMS \& BARS will be assess by trained trial center staff

    Time frame: Part A: 182 days; Part B: 126 days

  8. Investigator's assessment of injection site

    Injection site will be assessed. Injection site will also be inspected for seepage after needle is withdrawn.

    Time frame: Part A: 182 days; Part B: 126 days

  9. Visual analog scale (VAS) scores for pain reception

    Time frame: Part A: 182 days; Part B: 126 days

Secondary outcomes

  1. Maximum peak plasma concentration (Cmax) [Pharmacokinetics]

    Samples will also be collected on Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112, 126, 154, and 182/ET or until plasma concentrations of brexpiprazole are BLQ, whichever is longer based on monthly PK sampling (samples will be collected between 8 AM and 2 PM on the indicated nondosing day). If a PK blood sample cannot be drawn at the designated time on Day 1, a window of ± 15 minutes for each blood draw is acceptable with the exact time recorded. PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) including DM-3411.

    Time frame: Day 1 (predose [within 2 hours prior to dosing] and 4, 8 , and 12 hours postdose)

  2. Time of Cmax (tmax) [Pharmacokinetics]

    Samples will also be collected on Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112, 126, 154, and 182/ET or until plasma concentrations of brexpiprazole are BLQ, whichever is longer based on monthly PK sampling (samples will be collected between 8 AM and 2 PM on the indicated nondosing day). If a PK blood sample cannot be drawn at the designated time on Day 1, a window of ± 15 minutes for each blood draw is acceptable with the exact time recorded. PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) including DM-3411

    Time frame: Day 1 (predose [within 2 hours prior to dosing] and 4, 8 , and 12 hours postdose)

  3. Area under the concentration-time curve (AUC) from time zero to time "t" (Last observable concentration; AUCt) [Pharmacokinetics]

    Samples will also be collected on Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112, 126, 154, and 182/ET or until plasma concentrations of brexpiprazole are BLQ, whichever is longer based on monthly PK sampling (samples will be collected between 8 AM and 2 PM on the indicated nondosing day). If a PK blood sample cannot be drawn at the designated time on Day 1, a window of ± 15 minutes for each blood draw is acceptable with the exact time recorded. PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) including DM-3411

    Time frame: Day 1 (predose [within 2 hours prior to dosing] and 4, 8 , and 12 hours postdose)

  4. AUC from time zero to infinity (AUC∞) [Pharmacokinetics]

    Samples will also be collected on Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112, 126, 154, and 182/ET or until plasma concentrations of brexpiprazole are BLQ, whichever is longer based on monthly PK sampling (samples will be collected between 8 AM and 2 PM on the indicated nondosing day). If a PK blood sample cannot be drawn at the designated time on Day 1, a window of ± 15 minutes for each blood draw is acceptable with the exact time recorded. PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) including DM-3411

    Time frame: Day 1 (predose [within 2 hours prior to dosing] and 4, 8 , and 12 hours postdose)

  5. Terminal-phase elimination half-life (t1/2,z) [Pharmacokinetics]

    Samples will also be collected on Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112, 126, 154, and 182/ET or until plasma concentrations of brexpiprazole are BLQ, whichever is longer based on monthly PK sampling (samples will be collected between 8 AM and 2 PM on the indicated nondosing day). If a PK blood sample cannot be drawn at the designated time on Day 1, a window of ± 15 minutes for each blood draw is acceptable with the exact time recorded. PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) including DM-3411

    Time frame: Day 1 (predose [within 2 hours prior to dosing] and 4, 8 , and 12 hours postdose)

  6. Apparent clearance of drug from plasma after extravascular administration (CL/F; brexpiprazole only) [Pharmacokinetics]

    Samples will also be collected on Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112, 126, 154, and 182/ET or until plasma concentrations of brexpiprazole are BLQ, whichever is longer based on monthly PK sampling (samples will be collected between 8 AM and 2 PM on the indicated nondosing day). If a PK blood sample cannot be drawn at the designated time on Day 1, a window of ± 15 minutes for each blood draw is acceptable with the exact time recorded. PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) including DM-3411

    Time frame: Day 1 (predose [within 2 hours prior to dosing] and 4, 8 , and 12 hours postdose)

07

Study locations

2 sites
  • Collaborative Neuro Science (CNS)
    Garden Grove, California 92845, United States
  • CNRI
    San Diego, California 92102, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Dec 2017, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Nov 18, 2016
StartActual
Jan 2017
Primary completionActual
Dec 14, 2017
CompletionActual
Dec 14, 2017
Last update
Jan 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02968121
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Nov 18, 2016
Start date
Jan 2017
Primary completion
Dec 14, 2017
Completion
Dec 14, 2017
Last update
Jan 12, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion